5.44
前日終値:
$5.95
開ける:
$5.87
24時間の取引高:
169.13K
Relative Volume:
0.54
時価総額:
$120.10M
収益:
$66.59M
当期純損益:
$-104.93M
株価収益率:
-1.099
EPS:
-4.95
ネットキャッシュフロー:
$-96.48M
1週間 パフォーマンス:
-3.37%
1か月 パフォーマンス:
+15.01%
6か月 パフォーマンス:
-51.69%
1年 パフォーマンス:
-64.14%
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
名前
Enanta Pharmaceuticals Inc
セクター
電話
617 607 0800
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ENTA
Enanta Pharmaceuticals Inc
|
5.44 | 120.10M | 66.59M | -104.93M | -96.48M | -4.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
500.19 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
603.58 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
656.65 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
273.55 | 32.98B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
254.16 | 26.92B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-08-09 | ダウングレード | JP Morgan | Neutral → Underweight |
2023-08-08 | ダウングレード | Jefferies | Buy → Hold |
2022-12-09 | 開始されました | H.C. Wainwright | Buy |
2022-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
2022-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-09-09 | 開始されました | SVB Leerink | Mkt Perform |
2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
2020-11-24 | 開始されました | Evercore ISI | Underperform |
2020-08-28 | 再開されました | ROTH Capital | Buy |
2020-08-26 | 開始されました | Piper Sandler | Overweight |
2020-07-27 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
2020-03-17 | アップグレード | Robert W. Baird | Neutral → Outperform |
2019-11-22 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2019-09-26 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-05-24 | 開始されました | Wolfe Research | Outperform |
2019-04-23 | アップグレード | Berenberg | Hold → Buy |
2018-12-13 | 開始されました | Berenberg | Hold |
2018-06-06 | 開始されました | ROTH Capital | Buy |
2018-02-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2017-11-21 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-07-11 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
2016-04-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | 繰り返されました | Barclays | Underweight |
2015-10-23 | ダウングレード | Barclays | Equal Weight → Underweight |
2015-10-23 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
すべてを表示
Enanta Pharmaceuticals Inc (ENTA) 最新ニュース
Enanta Pharmaceuticals, Inc. (ENTA): The Best Breakout Stock to Buy According to Analysts - Yahoo Finance
JMP Securities maintains Enanta stock with $21 target - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
(ENTA) Investment Report - news.stocktradersdaily.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation At Escmid Global 2025 - marketscreener.com
Enanta Pharmaceuticals Announces Respiratory Syncytial Virus Data Presentation at ESCMID Global 2025 - Business Wire
Breakthrough RSV Treatment Achieves Double Success in Latest Clinical Trial - Stock Titan
(ENTA) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Enanta stock hits 52-week low at $4.71 amid market challenges - Investing.com Canada
Enanta stock hits 52-week low at $4.71 amid market challenges By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Not Doing Enough For Some Investors As Its Shares Slump 27% - simplywall.st
Enanta Pharmaceuticals at H.C. Wainwright: Strategic Shift to Immunology By Investing.com - Investing.com Canada
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Drug Co. Wants Fed. Circ. To Undo Pfizer COVID Patent Win - Law360
Enanta Reveals Latest Autoimmune Drug Progress: Key Presentation March 27 - StockTitan
How To Trade (ENTA) - Stock Traders Daily
Enanta Pharmaceuticals Reports Q1 EPS Loss of $1.05, Beating Est - GuruFocus.com
Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus Program at the 13 - Business Wire
Insider Buying: Jay Luly Acquires 45,000 Shares of Enanta Pharma - GuruFocus.com
Investor Network: Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Enanta Pharmaceuticals (NASDAQ:ENTA) Stock Crosses Below 200 Day Moving AverageHere's What Happened - MarketBeat
(ENTA) Trading Advice - Stock Traders Daily
Market Watch Highlights: Enanta Pharmaceuticals Inc (ENTA) Ends on an Upturn Note at 8.30 - The Dwinnex
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded at StockNews.com - MarketBeat
Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded to “Hold” at StockNews.com - Defense World
HC Wainwright Has Pessimistic Outlook of ENTA Q2 Earnings - MarketBeat
Enanta Pharmaceuticals' SWOT analysis: RSV and immunology drive stock outlook - MSN
Analysts Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25 - MarketBeat
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) CEO Purchases $256,050.00 in Stock - MarketBeat
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Cut to "Sell" at StockNews.com - MarketBeat
With Enanta Pharmaceuticals Up 46%, Insider Buyers Count Their Returns - Yahoo Finance
President of Enanta Pharmaceuticals Picks Up 5.9% More Stock - Yahoo Finance
Enanta Pharmaceuticals (ENTA) Moves to Buy: Rationale Behind the Upgrade - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Market Outperform" Rating from JMP Securities - MarketBeat
Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) Shares Bounce 55% But Its Business Still Trails The Industry - Simply Wall St
Enanta Pharmaceuticals’ (ENTA) “Buy” Rating Reiterated at HC Wainwright - Defense World
HC Wainwright maintains $18 target on Enanta shares, affirms Buy - MSN
Enanta Pharmaceuticals (NASDAQ:ENTA) Releases Quarterly Earnings Results - MarketBeat
Enanta Pharmaceuticals Advances in Virology and Immunology - TipRanks
Enanta Pharmaceuticals CEO Luly Jay R. buys $256,050 in common stock By Investing.com - Investing.com South Africa
Enanta Pharmaceuticals Inc (ENTA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):